CCDI™ is currently in development. We are seeking research, technology, and pilot collaborators.Collaborate With Us →

RESEARCH

Grounded in Evidence. Committed to Rigorous Science.

CCDI™ is being developed with a commitment to evidence-based methodology. Our research agenda spans clinical outcomes, interoperability standards, regulatory science, and real-world evidence generation in the medical cannabinoid space.

Development Status

CCDI™ is currently in development. Research publications, clinical data, and outcomes reports will be published here as the platform matures and data collection begins.

Research Philosophy

Evidence Informs. Clinicians and Patients Decide.

The CCDI™ platform is built on a foundational commitment to evidence-based practice. We do not prescribe, diagnose, or recommend. We build the infrastructure that makes evidence accessible, interpretable, and actionable at the point of care. Every design decision, data model, and integration standard is evaluated against this principle.

Methodological Rigor

Research conducted through or in partnership with CCDI™ will adhere to established clinical research standards, including peer review, transparent methodology, and reproducible findings.

Real-World Evidence

Our primary research focus is real-world evidence generation - capturing outcomes data from actual clinical and program contexts rather than controlled settings alone.

Interdisciplinary Collaboration

Meaningful research in this space requires collaboration across clinical medicine, pharmacology, health informatics, regulatory science, and public health. CCDI™ is designed to support that collaboration.

Transparency and Open Science

Where possible, CCDI™ research outputs will be published in open-access formats and data will be made available to the broader research community under appropriate data governance frameworks.

Research Agenda

Four Priority Research Areas.

01

Clinical Outcomes Research

In Development

Developing methodologies for collecting, analyzing, and applying real-world patient outcomes data across medical cannabinoid programs. This includes condition-specific outcomes frameworks, patient-reported outcome measures, and longitudinal tracking protocols.

Current Activities

  • Outcomes framework design for priority conditions
  • Patient-reported outcome measure selection and validation
  • Longitudinal data collection protocol development
  • Real-world evidence methodology standards
02

Interoperability and Data Standards

In Development

Advancing data standards and interoperability frameworks for cannabinoid clinical data exchange across healthcare and regulatory systems. This includes HL7 FHIR profile development, terminology mapping, and cross-system data governance.

Current Activities

  • HL7 FHIR profile development for cannabinoid clinical data
  • Terminology and coding standards mapping
  • Cross-system data governance framework design
  • EHR integration standards and API specifications
03

Regulatory Science

In Development

Supporting evidence-based approaches to state and federal regulatory frameworks for medical cannabinoid programs. This includes program evaluation methodology, compliance data infrastructure, and policy-relevant research outputs.

Current Activities

  • State program evaluation methodology development
  • Compliance and reporting data infrastructure design
  • Federal rescheduling impact analysis frameworks
  • Policy-relevant evidence synthesis and publication
04

Drug Interaction and Safety Research

In Development

Building and maintaining the evidence base for cannabinoid-drug interactions, contraindications, and safety signals. This includes systematic literature review, pharmacokinetic data synthesis, and clinical safety signal monitoring.

Current Activities

  • Systematic literature review of cannabinoid-drug interactions
  • Pharmacokinetic data synthesis and modeling
  • Clinical safety signal monitoring framework
  • Contraindication database development and maintenance

Publications

Research Publications

CCDI™ is in development. Peer-reviewed publications, white papers, and clinical data reports will appear here as research is completed and submitted for publication. We anticipate initial publications in 2025-2026.

Peer-Reviewed Research

Original research articles submitted to and published in peer-reviewed clinical and health informatics journals.

Forthcoming

White Papers

Policy-relevant white papers on regulatory science, data standards, and program design in the medical cannabinoid space.

Forthcoming

Clinical Data Reports

Outcomes data reports and real-world evidence summaries generated from CCDI™ platform data as the platform matures.

Forthcoming

Technical Standards

Published technical specifications, FHIR profiles, and interoperability standards developed through the CCDI™ research program.

Forthcoming

Research Partnerships

We Are Actively Seeking Research Partners.

CCDI™ is designed to support collaborative research across academic medical centers, clinical research organizations, health systems, and public health institutions. If your organization is conducting or planning research in the medical cannabinoid space, we want to hear from you.

Discuss a Research Partnership

Academic Medical Centers

Clinical research partnerships with academic medical centers conducting cannabinoid therapeutics research.

Clinical Research Organizations

CRO partnerships to support outcomes data collection, protocol development, and real-world evidence generation.

Public Health Institutions

Collaboration with schools of public health and public health agencies on program evaluation and population-level outcomes research.

Health Informatics Programs

Research partnerships with health informatics programs on interoperability standards, data governance, and clinical decision support methodology.

CCDI - Cannabinoid Clinical Decision Intelligence

Cannabinoid Clinical Decision Intelligence™

CCDIhealth.com

Platform Status

In Development

CCDI™ is actively seeking research, technology, and pilot collaborators.

Discuss a Collaboration →
Important Notice: The CCDI™ platform is in development and is not yet clinically validated or commercially available. Nothing on this website constitutes medical advice, diagnosis, treatment recommendations, or prescribing guidance.

© 2026 CCDI, Inc. All rights reserved. CCDI™ and Cannabinoid Clinical Decision Intelligence™ are trademarks of CCDI, Inc., a Delaware corporation.